These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25800023)

  • 1. Studies on the collision-induced dissociation of adipoR agonists after electrospray ionization and their implementation in sports drug testing.
    Dib J; Schlörer N; Schänzer W; Thevis M
    J Mass Spectrom; 2015 Feb; 50(2):407-17. PubMed ID: 25800023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
    Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
    Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry.
    Thevis M; Kohler M; Thomas A; Schlörer N; Schänzer W
    Rapid Commun Mass Spectrom; 2008 Aug; 22(16):2471-8. PubMed ID: 18634123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.
    Thevis M; Piper T; Beuck S; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1173-82. PubMed ID: 23650030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.
    Thevis M; Schänzer W
    Rapid Commun Mass Spectrom; 2016 Mar; 30(5):635-51. PubMed ID: 26842585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes.
    Höppner S; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2013 Jan; 27(1):35-50. PubMed ID: 23239315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for the calstabin-ryanodine receptor complex stabilizers JTV-519 and S-107 in doping control analysis.
    Thevis M; Beuck S; Thomas A; Kohler M; Schlörer N; Vajiala I; Schänzer W
    Drug Test Anal; 2009 Jan; 1(1):32-42. PubMed ID: 20355157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes.
    Höppner S; Delahaut P; Schänzer W; Thevis M
    J Pharm Biomed Anal; 2014 Jan; 88():649-59. PubMed ID: 24239904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for benfluorex and its major urinary metabolites in routine doping controls.
    Thevis M; Sigmund G; Gougoulidis V; Beuck S; Schlörer N; Thomas A; Kwiatkowska D; Pokrywka A; Schänzer W
    Anal Bioanal Chem; 2011 Aug; 401(2):543-51. PubMed ID: 21116611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electron ionization mass spectrometry of the ryanodine receptor-based Ca(2+)-channel stabilizer S-107 and its implementation into routine doping control.
    Thevis M; Beuck S; Thomas A; Fusshöller G; Sigmund G; Schlörer N; Rodchenkov G; Schäfer M; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Aug; 23(15):2363-70. PubMed ID: 19575395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots.
    Dib J; Tretzel L; Piper T; Lagojda A; Kuehne D; Schänzer W; Thevis M
    Clin Mass Spectrom; 2017 Dec; 6():13-20. PubMed ID: 39193415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry.
    Knoop A; Krug O; Vincenti M; Schänzer W; Thevis M
    Eur J Mass Spectrom (Chichester); 2015; 21(1):27-36. PubMed ID: 25906032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer.
    Thomas A; Geyer H; Schänzer W; Crone C; Kellmann M; Moehring T; Thevis M
    Anal Bioanal Chem; 2012 May; 403(5):1279-89. PubMed ID: 22231507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometry of hydantoin-derived selective androgen receptor modulators.
    Thevis M; Kohler M; Schlörer N; Kamber M; Kühn A; Linscheid MW; Schänzer W
    J Mass Spectrom; 2008 May; 43(5):639-50. PubMed ID: 18095383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annual banned-substance review: Analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H
    Drug Test Anal; 2018 Jan; 10(1):9-27. PubMed ID: 29149502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis.
    Thevis M; Kohler M; Maurer J; Schlörer N; Kamber M; Schänzer W
    Rapid Commun Mass Spectrom; 2007; 21(21):3477-86. PubMed ID: 17985352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
    Thevis M; Krug O; Schänzer W
    Rapid Commun Mass Spectrom; 2013 May; 27(9):993-1004. PubMed ID: 23592202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometric detection of peginesatide in human urine in doping control analysis.
    Möller I; Thomas A; Delahaut P; Geyer H; Schänzer W; Thevis M
    J Pharm Biomed Anal; 2012 Nov; 70():512-7. PubMed ID: 22884786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.
    Bredehöft M; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2008; 22(4):477-85. PubMed ID: 18236437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.